The Molecule That Ate Denmark
Sometime in late 2023, the Danish central bank did something unusual: it cut interest rates while the rest of Europe was still tightening. The reason had nothing to do with inflation expectations or slack in the labor market. It had to do with a single molecule — semaglutide — and the pharmaceutical company that manufactured it in a cluster of factories scattered across the flat countryside north of Copenhagen. Novo Nordisk's exploding exports of Ozempic and Wegovy had generated such an enormous current-account surplus that the Danish krone was threatening to break its peg to the euro, and the only way to relieve the pressure was to make Danish assets less attractive to foreign capital. A drug for Type 2 diabetes, repurposed as the most culturally consequential weight-loss treatment since the invention of the treadmill, had become so lucrative that it was distorting the monetary policy of a sovereign nation.
This is not a metaphor. Novo Nordisk's market capitalization — which peaked above $570 billion in 2024, briefly making it Europe's most valuable company, larger than LVMH, larger than the entire Danish
GDP — is the financial expression of a hundred-year bet on a single therapeutic area that the rest of pharma spent decades ignoring. The company controls roughly half the global insulin market. Its GLP-1 receptor agonist franchise, anchored by semaglutide, generated sales growth that made hardened Deutsche Bank analysts resort to words like "complete game changer." In the first half of 2023 alone, Novo's obesity care revenue surged 157% at constant exchange rates to DKK 18.1 billion. Total sales hit DKK 107.7 billion, up 30%. Operating profit rose 32%.
And yet the story of Novo Nordisk is not really about the money, or even the molecule. It is about what happens when a company decides — in a villa in Hellerup, Denmark, in 1923, and then again and again across a century of compounding institutional decisions — that the right response to a chronic disease is not to diversify away from it but to go deeper, and deeper, and deeper still.
By the Numbers
The Novo Nordisk Empire
DKK 232.3BNet sales, FY2023
~50%Global insulin market share
$570B+Peak market capitalization (2024)
69,000+Employees worldwide
157%Obesity care sales growth, H1 2023 (CER)
80Offices across the globe
100+Years of continuous diabetes focus
A Love Story as Origin Myth
The founding of Novo Nordisk is one of those origin stories that feel engineered for maximum narrative resonance — except it actually happened. Marie Krogh was among Denmark's first female medical graduates. Her husband, August Krogh, was a Nobel laureate in physiology, awarded the prize in 1920 for his work on capillary regulation. Marie had diabetes. In the early 1920s, that was a death sentence — a slow wasting that no amount of dietary restriction could arrest.
In 1921, a young Canadian surgeon named Frederick Banting and his assistant Charles Best extracted insulin from a dog's pancreas at the University of Toronto. The following year, a fourteen-year-old boy named Leonard Thompson, weighing just over 29 kilos, became the first human treated with the substance. Within twenty-four hours, his blood sugar levels dropped to near-normal. The news traveled fast.
At Marie's urging — this detail matters, because it was her disease, her insistence — August traveled to Canada to seek permission to produce insulin in Denmark. He returned with the technique and convinced Hans Christian Hagedorn, a brilliant and temperamental scientist, to join the effort alongside August Kongsted from Løvens Kemiske Fabrik. In March 1923, the first Danish patients received their insulin. Nordisk Insulinlaboratorium was born.
The founding was personal before it was commercial. Marie Krogh didn't want to diversify into adjacent therapeutic areas. She wanted to not die. That urgency — the patient as founder, the disease as origin — embedded something into the institutional DNA of the enterprise that would prove extraordinarily durable. For those interested in the full texture of the Kroghs' intertwined scientific and personal lives,
August and Marie Krogh: Lives in Science remains the definitive account.
The Sibling Rivalry That Built a Century
Two years after Nordisk began producing insulin, two brothers — Harald and Thorvald Pedersen, former Nordisk employees — walked out and formed their own company: Novo Terapeutisk Laboratorium. The split was acrimonious. It was also, in retrospect, the best thing that could have happened.
For sixty-four years, Novo and Nordisk competed viciously within the same small country, in the same narrow therapeutic category, against each other. This was not the kind of genteel Scandinavian cooperation that outsiders might imagine. Both companies built their own diabetes hospitals in the 1930s — Steno Memorial Hospital (Nordisk, 1932) and Hvidøre Diabetes Sanatorium (Novo, 1938) — not primarily out of philanthropy but because treating patients directly gave them clinical intelligence that informed product development. The hospitals were strategic assets disguised as acts of care.
⚔️
The Danish Insulin Wars
Two companies, one molecule, six decades of competition
1923Nordisk Insulinlaboratorium founded by Hagedorn and the Kroghs; first Danish patients treated with insulin.
1925Harald and Thorvald Pedersen leave Nordisk, found Novo Terapeutisk Laboratorium.
1932Nordisk establishes Steno Memorial Hospital for diabetes care and clinical research.
1938Novo opens Hvidøre Diabetes Sanatorium — the competitive response.
1946Hagedorn develops NPH insulin at Nordisk; becomes the world's dominant long-acting insulin.
1985Novo launches NovoPen, the world's first insulin delivery device resembling a pen.
1989Novo and Nordisk merge to form Novo Nordisk A/S after six decades of rivalry.
The rivalry forced innovation at a pace that a monopoly never would have. In 1946, Hagedorn developed NPH (Neutral Protamine Hagedorn) insulin — named after himself, naturally — which extended the duration of insulin action and reduced the injection burden for patients. NPH soon accounted for much of the world's consumption of longer-acting insulin. Novo, not to be outdone, invested heavily in purification technology and delivery systems, eventually producing the NovoPen in 1985 — the first insulin pen, a device so intuitive that it transformed the daily experience of millions of diabetics and established a delivery-device moat that competitors would spend decades trying to replicate.
When Novo and Nordisk finally merged in 1989, the combined entity inherited something rare: two distinct cultures of relentless incremental innovation within the same disease space, now unified under a single corporate structure with a shared foundation. The merger didn't kill the competitive energy. It internalized it.
The Architecture of Patient Captivity
What Novo Nordisk understood earlier than almost any pharmaceutical company — and what the rest of the industry is only now beginning to absorb — is that chronic disease is a platform business.
A patient diagnosed with Type 2 diabetes does not make a single purchasing decision. They make thousands of decisions, extending across decades: which insulin to use, which delivery device, which monitoring regime, which physician to trust. Each decision creates switching costs. The insulin pen that a patient learns to use at age forty-five is, in most cases, the pen they will use at sixty-five. The doctor who prescribes a particular analog insulin has trained their muscle memory around dosing protocols specific to that formulation. The insurer who negotiates a formulary placement creates a default that persists for years.
Novo Nordisk built its business around maximizing the surface area of these switching costs. The NovoPen wasn't just a delivery device — it was a razor-and-blade model. Once a patient (and their physician) committed to the pen platform, they were committed to Novo's proprietary insulin cartridges. The company invested in patient education programs, diabetes management apps, and clinical support services that deepened the relationship beyond the molecule itself. And by running its own diabetes hospitals since the 1930s, Novo accumulated a dataset of real-world patient outcomes that informed product development with a fidelity that clinical trials alone could never provide.
The result, over decades, was a market position of extraordinary stickiness. Novo Nordisk controls approximately half the global insulin market — a share that has remained remarkably stable even as competitors like Eli Lilly and Sanofi have launched their own modern insulin analogs. In a commodity business (insulin is, after all, a hundred-year-old molecule), that kind of share durability is almost unheard of. It suggests something deeper than brand loyalty. It suggests structural entrenchment.
The Willingness to Stay Narrow
The most remarkable strategic decision Novo Nordisk ever made is one it made continuously, by omission, for a century: it chose not to diversify.
This requires context. The pharmaceutical industry's dominant strategic paradigm for the past fifty years has been portfolio diversification — the idea that a drug company should spread its bets across multiple therapeutic areas to hedge against patent cliffs, regulatory setbacks, and clinical failures. Pfizer makes vaccines and oncology drugs and cardiovascular treatments. Roche does diagnostics and cancer. Johnson & Johnson does everything. The logic is straightforward: no single drug lasts forever, so you build a portfolio.
Novo Nordisk looked at this logic and said no.
The company did make selective forays into adjacent areas — growth hormones starting in the 1960s, hemophilia treatments, hormone replacement therapy. In 2000, it even spun off its enzyme business as Novozymes (a decision that itself reflected an almost fanatical commitment to focus). But the core of the enterprise remained diabetes. Decade after decade, as competitors diversified, Novo Nordisk went deeper into the metabolic system.
Ask chief executives why their companies are performing so well, and they'll typically credit a brilliant strategy coupled with hard-nosed, diligent execution. But when you ask Lars Sørensen of Novo Nordisk what forces propelled him to the top... he cites something very different: luck.
Lars Rebien Sørensen — who led Novo Nordisk as CEO from 2000 to 2016, was ranked as the best-performing CEO in the world by Harvard Business Review in 2015, and now chairs the Board of Directors — is an unusual figure for a pharma executive. Trained as a forester (his MSc from Copenhagen's Royal Veterinary and Agricultural University is in forestry) before earning a BSc in International Economics from Copenhagen Business School, Sørensen brought a naturalist's patience to corporate strategy. His instinct was to think in decades, not quarters. Under his leadership, Novo Nordisk didn't chase blockbuster opportunities in oncology or immunology. It invested — methodically, repetitively, almost boringly — in making its diabetes franchise incrementally better: better insulin analogs, better delivery devices, better patient outcomes, better relationships with endocrinologists.
The "luck" Sørensen cited was the explosion of Type 2 diabetes globally — from an estimated 30 million cases in 1985 to nearly 400 million by the time he gave that interview in 2015. But calling it luck obscures the strategic conviction required to remain concentrated in a single disease area for a century while the disease itself grew into a global pandemic. Novo Nordisk didn't get lucky. It got patient. The epidemic came to it.
The GLP-1 Epiphany
The scientific story behind semaglutide — the molecule that would become Ozempic and Wegovy and transform Novo Nordisk from a quietly excellent insulin company into the most talked-about pharmaceutical enterprise on Earth — is a masterclass in the kind of discovery that only happens when a company has spent decades immersed in a single biological system.
GLP-1 — glucagon-like peptide-1 — is a hormone produced in the gut that stimulates insulin secretion, suppresses glucagon release, and slows gastric emptying. It was identified in the 1980s. Researchers quickly realized it had potential for diabetes treatment: if you could mimic or extend GLP-1's activity, you could lower blood sugar without the weight gain and hypoglycemia risks associated with traditional insulin therapy.
The problem was that natural GLP-1 has a half-life of about two minutes. The body breaks it down almost immediately. Making a therapeutically useful GLP-1 drug required engineering a molecule that could survive long enough to do its work.
Novo Nordisk's scientists — and in particular Lotte Bjerre Knudsen, who would become the company's Chief Scientific Advisor — spent years working on this problem. The company launched liraglutide (branded as Victoza) in 2010 as a once-daily GLP-1 injection for Type 2 diabetes. It was a good drug, a meaningful advance. But the team pushed further. They engineered semaglutide — a modified GLP-1 analog designed to bind to albumin in the blood, extending its half-life to roughly a week. This single pharmacological trick — weekly dosing instead of daily — changed everything.
Ozempic (semaglutide for diabetes) received FDA approval in 2017. In 2018, its first full year on the market, Novo Nordisk's total net sales were approximately DKK 111.8 billion (roughly $17.7 billion). The drug was successful. It was not yet transformative.
The transformation came from an observation that was, in hindsight, almost obvious: patients on semaglutide were losing weight. Significant weight. The appetite-suppressing effects of GLP-1 receptor agonism — reduced hunger, earlier satiety, what patients described as the "silencing" of food noise — turned out to be not a side effect but perhaps the drug's most consequential mechanism of action.
The Wegovy Inflection
In June 2021, the FDA approved Wegovy — semaglutide at a higher dose (2.4 mg weekly) — for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. It was the first weight-loss drug to receive FDA approval in eight years.
What followed was unlike anything Novo Nordisk, or arguably any pharmaceutical company, had ever experienced.
Demand didn't just exceed forecasts. It obliterated them. In the last three months of 2022, U.S. healthcare providers wrote more than 9 million prescriptions for Ozempic, Wegovy, and related GLP-1 drugs. Ozempic accounted for more than 65% of those prescriptions. Social media influencers broadcast their weight-loss journeys.
Elon Musk tweeted about it. At the 2024 Academy Awards, host Jimmy Kimmel looked out at the audience and quipped about whether Ozempic was right for him. The laughter was knowing. Ozempic had become a one-word cultural shorthand, as immediately legible as Kleenex or Google.
It's clear that nobody had expected that it would be taking off this quickly. We all along knew that obesity was a serious chronic disease also when most others did not see it like that. So we knew we were onto something big.
In the first half of 2023, Wegovy sales surged 363%. Obesity care revenue leapt 157% at constant exchange rates to DKK 18.1 billion. Total company sales rose 30% to DKK 107.7 billion. Operating profit climbed 32%. Novo Nordisk's CFO, Karsten Munk Knudsen, who had been with the company for two decades, described the U.S. uptake as surpassing "anything we've ever seen before, not just by a few percent, but by severalfold."
The company was supply-constrained. Not margin-constrained, not demand-constrained, but literally unable to manufacture enough semaglutide to meet the market. Several European countries blocked exports of their GLP-1 stockpiles to the U.S. to protect domestic supply for actual diabetics. Novo reduced dosage strengths in some markets as a rationing measure. The scarcity, perversely, amplified the drug's cachet — creating an association with exclusivity and the Hollywood elite that no marketing campaign could have engineered.
At roughly $1,000 per month out-of-pocket in the U.S., the drugs were not cheap. That price point became its own cultural signal: this was a treatment for people who could afford it, which made the people who could afford it want it more. Goldman Sachs projected the global anti-obesity drug market would reach $100 billion annually by 2030. Analysts at Mizuho suggested that semaglutide alone could eventually be worth up to $300 billion in annual sales "over time."
The Foundation Structure: Governance as Moat
To understand Novo Nordisk's strategic behavior — its patience, its willingness to stay narrow, its century-long time horizon — you have to understand the thing that makes it structurally unlike almost any other major pharmaceutical company: its ownership.
Novo Nordisk is controlled by the Novo Nordisk Foundation, which holds approximately 28% of the company's shares but controls a majority of voting rights through a dual-class share structure. The Foundation, in turn, holds its stake through Novo Holdings A/S, a massive investment vehicle that also owns Novozymes and maintains a portfolio of life-science investments.
The Foundation's charter mandates that it provide "a stable basis for the commercial and research activities" of Novo Nordisk. Its assets, swollen by the company's share price appreciation, reportedly exceeded those of the Gates Foundation by 2024 — making it the world's largest philanthropic foundation. It channels billions into scientific research, healthcare infrastructure, and education, primarily in Denmark.
This structure has profound implications. A foundation-controlled company does not face the same activist-investor pressure to return capital, pursue short-term earnings beats, or diversify into trendy therapeutic areas. It can invest in twenty-year R&D programs without quarterly conference calls full of analysts asking why the money wasn't spent on share buybacks. It can maintain a "Triple Bottom Line" principle — enshrined in Novo Nordisk's Articles of Association — requiring that business decisions balance financial, social, and environmental considerations, without worrying that a hostile bidder will argue this is a misallocation of shareholder value.
The Novo Nordisk Way — the company's internal governance document, based on principles established by its founders — codifies this orientation: "When faced with difficult choices, we think long-term, understanding that our future is dependent on adding value to society by being financially, environmentally and socially responsible."
Critics might argue that foundation control insulates management from market discipline. That's true. It's also, arguably, why the company was willing to spend decades building out GLP-1 science when shorter-time-horizon competitors would have pivoted to higher-expected-value programs. The governance structure didn't just protect patience. It demanded it.
The Nokia Risk
Novo Nordisk's extraordinary success has created an equally extraordinary vulnerability — not for the company, but for its home country.
By 2024, Novo's market capitalization exceeded Denmark's entire GDP. Its income tax bill in Denmark was $2.3 billion in 2023. Its manufacturing investments and heightened production helped the Danish economy expand nearly 2% — more than four times the EU average. Without Novo's contribution, the Danish economy would have stagnated. Danish pension funds were flush from record returns on Novo shares. Mortgages were cheaper because the central bank had to suppress interest rates to manage the krone peg. Politicians considered the company's perspective before making decisions on immigration policy or infrastructure development. Educational and research priorities were influenced by the company's agenda.
Economists call this the "Nokia risk" — a reference to the Finnish telecom giant whose decline in the 2000s dragged down Finland's entire economy, wiping out jobs, gutting university research funding, and cratering the supplier ecosystem that had built up around it. Novo Nordisk's CEO at the time, Lars Fruergaard Jørgensen, acknowledged the dynamic with a characteristically Scandinavian reference: "When you have superpowers," he said, citing the Swedish children's story Pippi Longstocking, "you have super responsibility."
The cultural dimension is revealing. Denmark has janteloven — an unofficial social code discouraging flashy displays of success. When Novo rented Copenhagen's Tivoli Gardens for a private staff party in September 2023, it asked employees not to post photos on social media "for fear of repercussions." The company quietly reduced Ozempic prices in Denmark by nearly a third following months of public debate over rising medication costs. A company that dominates its country's economy must navigate its culture with a delicacy that a global giant based in New York or Basel simply doesn't face.
The Succession and the Supply Problem
In August 2025, Novo Nordisk replaced Lars Fruergaard Jørgensen as CEO with Mike Doustdar — a choice that itself reads as a strategic signal.
Doustdar's biography is the company's international ambitions made flesh. Born in Iran, raised in the United States, educated in Austria (BA in International Business, Webster University, Vienna, 1994), he joined Novo Nordisk in 1992 as an office clerk in Vienna. Over thirty-three years he rose through finance, IT, logistics, operations, and marketing across the company's emerging markets — Near East, Oceania, Southeast Asia — before being appointed executive vice president of International Operations in 2015. By 2025, his portfolio included all global commercial units excluding the USA.
The appointment of an operations-and-commercial lifer, rather than a scientist or a strategist, suggested that the board's diagnosis of the company's most pressing challenge was not innovation but execution: manufacturing enough semaglutide to satisfy a demand curve that showed no sign of bending downward, while simultaneously navigating the U.S. pricing debate, the regulatory complexity of global weight-loss drug markets, and the competitive threat from Eli Lilly's tirzepatide (Mounjaro/Zepbound).
Lilly's entry was the first truly credible competitive challenge to Novo's GLP-1 dominance. Tirzepatide, a dual GIP/GLP-1 receptor agonist, showed weight loss results that in some trials exceeded those of semaglutide. Mounjaro received FDA approval for Type 2 diabetes in May 2022; Zepbound, its obesity-indication version, followed. Pfizer and other companies were developing their own GLP-1 programs. The market Novo Nordisk had essentially created was, inevitably, attracting entrants.
Meanwhile, compounding pharmacies exploited an FDA provision allowing reproduction of drugs on the shortage list, creating a $1 billion annual market in unvetted semaglutide knockoffs. The market for Ozempic alone was estimated at $11 billion in 2024 and projected to hit $16.5 billion by 2029. Not all of that revenue was flowing to Novo Nordisk.
The Paradox of the Patient Company
The central paradox of Novo Nordisk is this: a company whose greatest competitive advantage is patience is now operating in a market that demands speed.
For a century, Novo Nordisk's strategy was to go deeper, not wider — to invest in the slow accumulation of manufacturing expertise, clinical data, physician relationships, and patient loyalty within a single disease space. That strategy was perfectly suited to the insulin market, which rewards reliability, incremental improvement, and institutional trust over flash. Diabetes care is a marathon. Novo trained for marathons.
The GLP-1 obesity market is a sprint. Demand materialized at a pace that outstripped manufacturing capacity. Competitive entrants arrived within years, not decades. The political economy of weight-loss drugs — pricing controversies, insurance coverage battles, cultural debates about medicalization — moves at the speed of social media, not the speed of clinical trials. Novo Nordisk must now simultaneously defend its insulin franchise, scale semaglutide production globally, develop next-generation obesity treatments (oral semaglutide, higher-efficacy analogs, combination therapies), manage a CEO transition, navigate the most hostile U.S. drug-pricing environment in a generation, and preserve the institutional culture that made all of this possible in the first place.
When you have superpowers, you have super responsibility.
Whether a company that spent a century learning to be patient can learn to be fast — without losing the thing that made its patience so valuable — is the question that will define Novo Nordisk's next decade. The foundation structure provides a shock absorber. The scientific pipeline provides optionality. The brand provides pricing power. But the market capitalization prices in a future where supply catches demand, where competitors don't catch up, and where the political system doesn't radically restructure the economics of weight-loss drugs. That's a lot of assumptions.
In Hillerød, a town better known for its four-hundred-year-old castle, twenty-six miles north of Copenhagen, blue Ozempic pens and white Wegovy pens zip along factory assembly lines in a blur. At $1,000 a month per patient, with an addressable population in the hundreds of millions, each pen that rolls off the line represents a tiny claim on the most consequential pharmacological franchise of the twenty-first century — conceived in a villa in Hellerup, funded by a foundation chartered to think in centuries, and built by a company that took a hundred years to become an overnight sensation.
Novo Nordisk's century of compounding advantage didn't arise from a single stroke of brilliance but from a set of operating principles — some deliberate, some emergent — that reinforced one another across decades. What follows are the principles most relevant to operators building durable businesses in complex, regulated, and science-intensive markets.
Table of Contents
- 1.Let the patient be the founder.
- 2.Go deeper, not wider.
- 3.Compete with yourself before anyone else does.
- 4.Own the delivery system, not just the molecule.
- 5.Build the hospital to understand the patient.
- 6.Engineer your governance for patience.
- 7.Let the epidemic come to you.
- 8.Promote from the inside, especially through the periphery.
- 9.Make the side effect the main event.
- 10.Treat supply as strategy, not logistics.
Principle 1
Let the patient be the founder.
Marie Krogh didn't invest in diabetes care as an abstraction. She had diabetes. The urgency was existential. That personal stake — the founder as end-user — embedded a specific kind of empathy into the organization that no market research department can replicate.
Companies built by people who viscerally understand the problem they're solving develop different intuitions about product design, about acceptable tradeoffs, about what "good enough" means. Marie didn't want a treatment that was merely pharmacologically effective; she wanted one that made life livable. That orientation — the patient as the ultimate design constraint — became codified in the Novo Nordisk Way and persists in the company's "10 Essentials," the first of which reads: "We create value by having a patient-centred business approach."
The deeper lesson isn't that every founder needs to have the disease their company treats. It's that proximity to the problem — genuine, uncomfortable, daily proximity — creates an informational advantage that compounds over time. Novo's decision to build its own diabetes hospitals in the 1930s was a formalization of this principle: if you can't be the patient, get as close to them as operationally possible.
Benefit: Founder-as-patient creates a cultural immune system against strategic drift. When the customer's pain is the company's origin story, diversification for its own sake feels like betrayal.
Tradeoff: It can produce tunnel vision. Novo Nordisk was slow to recognize the obesity opportunity sitting inside its own clinical data because the institutional identity was so thoroughly organized around diabetes.
Tactic for operators: If you don't have the problem you're solving, design systematic mechanisms to close the gap — shadow programs, customer advisory boards with veto power, embedded ethnographic research. The information asymmetry between you and your customer is the single largest source of strategic error.
Principle 2
Go deeper, not wider.
For a century, while the rest of pharma diversified into oncology, immunology, neuroscience, and consumer health, Novo Nordisk stayed in metabolic disease. The 2000 spinoff of Novozymes — the enzyme business — was the definitive expression of this principle: even a profitable, growing, scientifically interesting business was divested because it diluted the focus.
Novo Nordisk's R&D allocation vs. diversified pharma
| Company | Therapeutic Areas | Core Focus Share |
|---|
| Novo Nordisk | Diabetes, Obesity, Rare Blood Disorders | ~90%+ diabetes/obesity |
| Pfizer | Oncology, Vaccines, Internal Medicine, Rare Disease | ~25–30% per area |
| Roche | Oncology, Immunology, Neuroscience, Diagnostics | ~50% oncology |
| Eli Lilly | Diabetes, Oncology, Immunology, Neuroscience | ~40% diabetes/obesity |
This concentration created compounding returns in institutional knowledge. Every clinical trial, every manufacturing process, every regulatory filing added to a cumulative understanding of metabolic biology that diversified competitors couldn't match in any single area. When the GLP-1 opportunity emerged, Novo had the scientific depth, the physician relationships, the manufacturing infrastructure, and the regulatory expertise to move faster than anyone else — not because it was more innovative in absolute terms, but because it had been innovating in the same narrow domain for eight decades.
Benefit: In knowledge-intensive industries, depth compounds. The tenth insulin analog you develop draws on insights from the first nine. Diversified competitors spread that learning curve across a dozen therapeutic areas.
Tradeoff: Concentration risk is real. If diabetes were ever "solved" — through prevention, gene therapy, or radical dietary change — Novo's franchise would collapse. The obesity pivot mitigated this somewhat, but the company remains a one-system bet.
Tactic for operators: Before diversifying into an adjacent market, ask whether you've exhausted the depth of your current one. The most defensible businesses are often the ones that look boringly narrow from the outside but have accumulated irreplaceable institutional knowledge on the inside.
Principle 3
Compete with yourself before anyone else does.
The sixty-four-year rivalry between Novo and Nordisk — before their 1989 merger — is the most literal version of this principle possible: the company's competitive intensity was internal. After the merger, this spirit persisted in a more subtle form. Each generation of insulin analog was designed to cannibalize the previous one. The NovoPen replaced syringes that Novo was already selling. Ozempic threatened Victoza's franchise. Wegovy opened a market that could reduce demand for insulin itself, if obesity treatment prevented the progression to Type 2 diabetes.
This willingness to cannibalize — to attack your own revenue streams before a competitor does — requires a particular kind of institutional confidence. You have to believe that the next product will be better, that your manufacturing and distribution capabilities will extend your advantage even as the underlying molecule changes, and that the patient relationship you've built will survive the transition. Novo Nordisk believed all of these things, and acted accordingly.
Benefit: Self-cannibalization preempts disruption. If you don't obsolete your own product, someone else will — on their timeline, with their economics.
Tradeoff: It requires absorbing short-term revenue compression and the organizational discomfort of telling a successful sales team that their franchise is being replaced. Not every company culture can sustain this.
Tactic for operators: Build the replacement product before the incumbent product peaks. If you wait until decline is visible, you've already lost the initiative. The ideal time to launch the successor is when the predecessor is still growing.
Principle 4
Own the delivery system, not just the molecule.
The NovoPen, launched in 1985, was not just a product innovation — it was a strategic architecture decision. By creating a proprietary delivery device that required proprietary insulin cartridges, Novo transformed a commodity molecule into a system sale. The pen created switching costs that the molecule alone couldn't. Patients trained on a specific pen don't casually switch to a competitor's device; physicians who learn to dose around a specific system don't casually re-educate themselves.
This is the razor-and-blade model applied to biologics. The insight is transferable: in any market where the active ingredient is (or will become) commoditized, owning the delivery mechanism — the interface through which the customer experiences the product — creates defensibility that the product itself cannot.
Benefit: Delivery-system lock-in generates recurring revenue and switching costs that survive patent expirations. Novo's insulin pen franchise has remained dominant for nearly four decades.
Tradeoff: It requires sustained investment in hardware design and manufacturing — capabilities that are orthogonal to pharma's core competency in chemistry and biology. This is operationally expensive and culturally awkward for a science-driven organization.
Tactic for operators: Ask where the customer interface is in your product. If you only control the "ingredient" but not the "container," you're vulnerable to someone who controls the container commoditizing your ingredient.
Principle 5
Build the hospital to understand the patient.
Both Novo and Nordisk built their own diabetes hospitals in the 1930s — a decision that, viewed from today's pharmaceutical industry norms, is almost incomprehensible. Why would a drug company run a hospital?
The answer is informational. By treating patients directly, both companies gained real-world clinical intelligence that was orders of magnitude richer than anything available from contracted clinical trials. They saw how patients actually used insulin, what dosing patterns produced the best outcomes, what comorbidities complicated treatment, what quality-of-life factors mattered most. This intelligence fed directly back into R&D, creating a feedback loop between bedside observation and laboratory innovation.
When the two hospitals merged in 1992 to form the Steno Diabetes Center, the combined institution became one of the world's preeminent diabetes research and treatment facilities — and a strategic asset for Novo Nordisk that no amount of money could have bought on the open market.
Benefit: Direct patient contact creates an unforgeable informational moat. You see things that surveys and CROs miss.
Tradeoff: Running healthcare institutions is capital-intensive, regulatory-complex, and exposes the company to operational liabilities far removed from drug manufacturing.
Tactic for operators: You probably can't build a hospital. But you can embed yourself in your customer's workflow deeply enough to observe their unspoken needs. The most valuable product insights come from watching people struggle with your current product in real time.
Principle 6
Engineer your governance for patience.
The Novo Nordisk Foundation's controlling stake is the single most important structural feature of the company, and the one that enables almost every other principle on this list. A foundation with a century-long charter does not think in quarters. It does not respond to activist investors demanding share buybacks. It does not fire a CEO for pursuing a twenty-year R&D program that depresses near-term margins.
The "Triple Bottom Line" principle in Novo's Articles of Association — financial, social, and environmental responsibility — is not a marketing tagline. It is a governance constraint that the foundation enforces. This constraint, paradoxically, creates strategic freedom: because management doesn't need to optimize for next quarter's EPS, it can invest in the kind of deep, patient, infrastructure-heavy R&D that produces semaglutide-class breakthroughs.
Benefit: Long-duration governance structures allow long-duration strategy. Novo's GLP-1 program took decades from initial research to commercial explosion. Few publicly traded companies with standard governance could have sustained that investment.
Tradeoff: Foundation control can insulate management from market discipline, permitting mediocrity to persist. It also creates complex principal-agent problems: the foundation's interests and the minority shareholders' interests don't always align.
Tactic for operators: If you can't create foundation-like governance, find other structural mechanisms to extend your time horizon — long-vesting equity, dual-class shares, patient anchor investors, or simply building a culture where "long-term" is defined in decades rather than years.
Principle 7
Let the epidemic come to you.
Novo Nordisk didn't create the global diabetes epidemic. It positioned itself to be the company best prepared when the epidemic arrived. The global prevalence of Type 2 diabetes grew from an estimated 30 million cases in the 1980s to close to 400 million by 2015. Obesity — now the company's fastest-growing market — affects over 650 million adults worldwide, with rates still climbing.
These epidemiological trends were visible decades in advance. The connection between rising obesity rates, sedentary lifestyles, processed food consumption, and metabolic disease was well-understood by public health researchers long before it showed up in pharmaceutical revenue. Novo's advantage was not in predicting these trends — everyone could see them — but in having the depth of capability to capture the resulting demand when it materialized.
Benefit: Positioning for secular trends that are visible but slow-moving creates enormous optionality. You don't need to time the market; you just need to be ready when it arrives.
Tradeoff: Secular trends can reverse, plateau, or be disrupted by policy interventions (public health campaigns, sugar taxes, preventive medicine). Building your business on a disease epidemic carries moral and strategic risk if the epidemic is eventually controlled.
Tactic for operators: Identify the secular forces — demographic, epidemiological, technological — that will create demand ten to twenty years from now. Then invest in the capabilities to serve that demand, even if the timing is uncertain. Being early is better than being fast.
Principle 8
Promote from the inside, especially through the periphery.
Novo Nordisk's leadership pipeline is almost entirely internal. Lars Rebien Sørensen joined the company's enzyme division (later Novozymes) in 1982 and spent eighteen years inside the organization before becoming CEO. Lars Fruergaard Jørgensen, his successor, was a career Novo Nordisk executive. Mike Doustdar, the current CEO, joined as an office clerk in Vienna in 1992 and spent thirty-three years rising through the company's international operations.
The pattern is notable not just for its insiderness but for its geography. Both Jørgensen and Doustdar developed their careers substantially outside Denmark — in the company's international markets, the places where growth was fastest and organizational complexity highest. Novo Nordisk treats its emerging-market operations not as exile but as leadership training.
Benefit: Internal promotion preserves institutional knowledge and cultural continuity. Leaders who have spent decades inside the system understand its informal power structures, its scientific rhythms, and its patient-first culture in a way that external hires cannot.
Tradeoff: Insularity risks groupthink. An organization that only promotes from within may miss disruptive strategic shifts that an outsider would recognize immediately.
Tactic for operators: If you promote from within, make sure the internal pipeline includes people who have operated at the company's edges — in new markets, in turnaround situations, in roles that required them to build something from nothing. The periphery is where the most generalizable leadership skills are forged.
Principle 9
Make the side effect the main event.
The weight-loss properties of GLP-1 agonists were, initially, a clinical observation buried in the side-effect profile of a diabetes drug. Patients on liraglutide and semaglutide reported reduced appetite and weight loss. For years, this was a secondary finding — interesting but not the primary endpoint.
Novo Nordisk had the scientific fluency to recognize that this "side effect" was potentially more valuable than the intended effect. The company invested in clinical trials specifically designed to test semaglutide as an obesity treatment, eventually securing FDA approval for Wegovy in 2021. That pivot — from diabetes drug with weight-loss side effects to weight-loss drug with diabetes benefits — unlocked a market that analysts now project at $100 billion annually.
Benefit: Deep domain expertise allows you to recognize the significance of unexpected findings. Generalist companies would have dismissed weight loss as a secondary outcome; Novo's metabolic-system expertise allowed it to see the full pharmacological picture.
Tradeoff: Repurposing a drug for a new indication requires navigating a new regulatory pathway, a new payer landscape, and a new patient population — each with its own complexities. Novo's supply constraints are a direct consequence of demand from a market segment the company was not originally designed to serve.
Tactic for operators: Pay attention to the unexpected ways customers are using your product. The most valuable pivot opportunities often hide in behavior you didn't intend and data you're not collecting on purpose.
Principle 10
Treat supply as strategy, not logistics.
Novo Nordisk's post-Wegovy supply crisis revealed a truth that the company had known implicitly for decades but that the market had not yet priced in: in biologics, manufacturing is the moat.
Producing semaglutide at scale requires fermentation, purification, and fill-finish capabilities that take years to build and certify. You cannot outsource this to a contract manufacturer and scale overnight. Novo's century of insulin manufacturing experience gave it the closest thing to ready-made capacity, but even that was insufficient for the demand surge. The company has committed billions to expanding production — new facilities, expanded existing sites, accelerated construction timelines — because every month of supply constraint is a month of lost revenue and competitive vulnerability.
Benefit: In markets with high manufacturing barriers, capacity itself is a competitive weapon. If you can make more product than your competitor, you win — regardless of whose molecule is marginally superior.
Tradeoff: Manufacturing capacity requires massive capital investment with long lead times. If demand forecasts prove wrong — if GLP-1 adoption slows, if competition fragments the market, if oral alternatives reduce injectable demand — overcapacity becomes a balance-sheet drag.
Tactic for operators: In any business with physical production constraints, start building capacity before you need it. The companies that win supply-constrained markets are the ones that invested in manufacturing when the market still looked speculative.
Conclusion
The Compounder's Dilemma
Novo Nordisk's century-long story is, at its core, about the power and peril of compounding. Compound your knowledge in a single domain, and you eventually see things no one else can see — a side effect that is actually a market worth $100 billion. Compound your manufacturing expertise, and you build capacity that competitors cannot replicate. Compound your patient relationships, and you create switching costs that survive patent expirations. Compound your governance patience, and you can invest in twenty-year bets that quarterly-focused competitors cannot stomach.
But compounding also creates concentration. The same narrowness that generated Novo's GLP-1 breakthrough makes it vulnerable to disruption from outside the metabolic system. The same foundation governance that enabled patience may also enable complacency. The same Danish cultural embeddedness that gives the company its institutional soul also creates the Nokia risk for an entire nation.
The playbook, then, is not a recipe for guaranteed success. It is a set of principles for building deep, durable competitive advantage in a specific kind of market — one where the disease is chronic, the science is complex, the manufacturing is hard, and the time horizon is measured in decades. For operators building in those conditions, Novo Nordisk is the proof that patience, relentlessly compounded, is the most powerful force in business. For operators in faster-moving markets, it is a cautionary tale about what happens when a century of depth meets a market that suddenly demands breadth.
Part IIIBusiness Breakdown
The Business at a Glance
Current Vital Signs
Novo Nordisk — Mid-2025
DKK 232.3BNet sales, FY2023 (~$34B)
~42%Operating profit margin, FY2023
$350B+Market capitalization (mid-2025, post-correction)
69,000+Employees globally
~50%Global insulin market share
30%+Revenue growth rate, FY2023 (CER)
80Countries with direct operations
Novo Nordisk is the world's largest producer of insulin and the dominant player in the rapidly expanding GLP-1 receptor agonist market. Headquartered in Bagsværd, Denmark, listed on the Copenhagen Stock Exchange (Novo-B) and trading as ADRs on the NYSE (NVO), the company is controlled by the Novo Nordisk Foundation through a dual-class share structure. As of mid-2025, it remains Europe's most valuable or second-most-valuable company depending on the day, having experienced significant share price volatility tied to competitive developments with Eli Lilly, clinical trial readouts, and political debates over U.S. drug pricing.
The company's FY2023 results captured a business in explosive transition: total net sales rose approximately 31% at constant exchange rates to DKK 232.3 billion. North America Operations — the engine of GLP-1 growth — grew approximately 45% in Danish kroner. The Diabetes and Obesity care segment, representing the vast majority of revenue, grew 36%, driven by GLP-1 diabetes sales growth of roughly 50% and Obesity care (principally Wegovy and Saxenda) surging over 150%. The Rare Disease segment — hemophilia and growth hormone treatments — represented a smaller and temporarily compressed portion of the business.
How Novo Nordisk Makes Money
Novo Nordisk's revenue derives from three therapeutic platforms, with radically different growth trajectories and competitive dynamics.
FY2023 approximate revenue breakdown
| Segment | Key Products | Est. Revenue (DKK) | Growth (CER) | Status |
|---|
| GLP-1 Diabetes | Ozempic, Victoza, Rybelsus | ~125B | ~50% | Growth |
| Insulin | Tresiba, Levemir, NovoRapid, Fiasp | ~55B | Low single digits | Mature |
| Obesity Care |
GLP-1 Diabetes (Ozempic/Rybelsus): The franchise anchor. Semaglutide for diabetes — injectable (Ozempic) and oral (Rybelsus) — has become the standard of care for Type 2 diabetes management in markets that can afford it. Ozempic accounted for more than 65% of all GLP-1 prescriptions in the U.S. as of late 2022, and share has remained elevated. Novo holds a U.S. patent on semaglutide until 2032, providing significant near-term pricing protection. Average net realized price in the U.S. is substantially higher than in international markets due to the structure of the PBM/rebate system, making North America the company's profit engine.
Obesity Care (Wegovy/Saxenda): The fastest-growing and most culturally visible segment. Wegovy (semaglutide 2.4 mg) is priced at roughly $1,000/month out-of-pocket in the U.S. Demand has consistently outstripped supply since launch. The SELECT cardiovascular outcomes trial, announced in August 2023, demonstrated that semaglutide 2.4 mg significantly reduced the risk of major adverse cardiovascular events — a finding that dramatically expanded the reimbursement case by proving the drug is not merely cosmetic but medically consequential.
Insulin: The legacy franchise. Still enormous — roughly half the global market — but growing slowly as GLP-1s increasingly become first-line therapy for Type 2 diabetes. Insulin remains critical for Type 1 diabetes and advanced Type 2, providing a stable revenue base. Tresiba (insulin degludec) and Fiasp (fast-acting insulin aspart) are the flagship modern analogs.
Rare Disease: Growth hormones (Norditropin) and hemophilia treatments (NovoSeven, Esperoct). A smaller business that experienced temporary manufacturing-related revenue declines in 2023. Strategically important for diversification but not a growth driver.
The unit economics of the GLP-1 franchise are extraordinary by pharmaceutical standards. Semaglutide is a biologic — produced through fermentation of genetically engineered yeast — with high manufacturing costs but even higher pricing power. Gross margins across the business are estimated above 80%. Operating margins have expanded toward 42–45% as the high-margin GLP-1 and obesity mix has grown relative to the lower-margin insulin base.
Competitive Position and Moat
Novo Nordisk's competitive moat is multi-layered but faces its most serious challenge in a generation.
Moat Source 1: Manufacturing Scale and Expertise. Producing injectable biologics at the scale Novo operates — billions of doses annually — requires fermentation, purification, and fill-finish infrastructure that takes years to build and regulatory approval to operate. No competitor can replicate this capacity quickly. Novo has committed tens of billions of DKK to manufacturing expansion, including new facilities in Denmark and internationally.
Moat Source 2: Physician and Payer Relationships. A century of diabetes focus has created deep institutional relationships with endocrinologists, primary care physicians, and payer formulary committees. These relationships create prescribing inertia — the tendency for physicians to default to the brand they know and trust.
Moat Source 3: Patent Protection. Semaglutide's U.S. patent extends to 2032. This provides a window of near-exclusive pricing power in the company's most profitable market. Beyond semaglutide, Novo's pipeline includes next-generation molecules (CagriSema, amycretin) with their own patent protection.
Moat Source 4: Delivery Device Lock-In. The FlexTouch pen platform and accompanying patient training create meaningful switching costs. A patient who has learned to self-inject with a Novo device does not casually switch to a competitor's device.
Moat Source 5: Clinical Data Superiority. The SELECT cardiovascular outcomes trial for Wegovy, and extensive real-world data from decades of GLP-1 prescribing, give Novo a clinical evidence base that newer entrants cannot yet match.
⚔️
The Competitive Landscape
Key GLP-1/obesity competitors and their positions
| Competitor | Key Product | Mechanism | Status | Threat Level |
|---|
| Eli Lilly | Mounjaro / Zepbound (tirzepatide) | Dual GIP/GLP-1 agonist | Approved, scaling | High |
| Amgen | MariTide | Bispecific antibody (GLP-1/GIPR) | Phase 2/3 | Medium |
| Pfizer |
The honest assessment: Eli Lilly is a formidable competitor. Tirzepatide's dual-agonist mechanism has shown weight-loss results in some trials that rival or exceed semaglutide's. Lilly is scaling manufacturing aggressively and has deep U.S. commercial capabilities. The GLP-1 obesity market will not be a monopoly — it will be a duopoly at minimum, and potentially a broader competitive market within five to seven years as pipeline candidates advance.
Novo's moat in insulin remains robust but slowly eroding as biosimilar competition intensifies and GLP-1s displace insulin as first-line therapy. In obesity, the moat is real but time-limited — semaglutide's clinical evidence advantage will narrow as competitors generate their own outcomes data, and manufacturing scale advantages will diminish as Lilly and others invest in capacity.
The Flywheel
Novo Nordisk's competitive compounding machine operates through a reinforcing cycle that has spun faster with each decade.
🔄
The Novo Nordisk Flywheel
How century-deep domain focus compounds into market dominance
Step 1Deep domain focus in metabolic disease generates unrivaled biological and clinical understanding of diabetes and obesity pathways.
Step 2That understanding produces incrementally superior molecules, devices, and treatment protocols — each building on decades of accumulated data.
Step 3Superior products attract physician prescribing loyalty and formulary placement, driving market share and revenue growth.
Step 4Revenue and foundation governance fund sustained R&D reinvestment at a level that diversified competitors cannot match in any single therapeutic area.
Step 5Manufacturing expertise built over a century allows faster scaling and higher quality than new entrants, creating supply-side competitive advantage.
Step 6Dominant market position generates real-world outcomes data from millions of patients, further informing next-generation product development.
The flywheel's key accelerant is data density. Because Novo treats more diabetic and obese patients than any other company — through its own products, its clinical trials, and its Steno Diabetes Center — it accumulates real-world evidence faster than competitors. That evidence informs both product development and regulatory strategy (the SELECT trial, for instance, was designed specifically to generate the cardiovascular outcomes data needed to expand reimbursement). The data flywheel is the hardest element for competitors to replicate, because it is a function of time and patient volume, neither of which can be purchased.
Growth Drivers and Strategic Outlook
Five specific growth vectors will determine Novo Nordisk's trajectory over the next five to ten years.
1. Obesity Market Expansion. Goldman Sachs estimates the global anti-obesity drug market will reach $100 billion annually by 2030. Novo's current obesity care revenue run rate (annualizing H1 2023 figures) is approximately DKK 36 billion (~$5.2 billion). The gap between current revenue and the total market opportunity is enormous. Key catalysts include expanding insurance coverage (the SELECT cardiovascular outcomes data is critical here), supply normalization, and geographic expansion beyond the U.S.
2. Oral Semaglutide Scale-Up. Rybelsus (oral semaglutide for diabetes) has grown but remains a small fraction of the franchise. Higher-dose oral semaglutide formulations for obesity — which would eliminate the injection barrier — are in development. An effective oral obesity drug could dramatically expand the addressable market by reaching patients who refuse injectables.
3. Next-Generation Molecules. CagriSema (semaglutide + cagrilintide, a dual amylin/GLP-1 agonist) and amycretin (a novel amylin analog) represent Novo's pipeline defense against competitive erosion. If these molecules deliver superior weight loss or better metabolic profiles than semaglutide alone, they extend the franchise beyond the 2032 patent cliff.
4. Cardiovascular and NASH/MASH Indications. The SELECT trial's cardiovascular benefit finding opens a pathway to prescribe semaglutide not just for weight loss but for cardiovascular risk reduction — a much larger reimbursement-eligible population. Semaglutide's effects on metabolic-associated steatohepatitis (MASH, formerly NASH) are also under investigation, representing another multi-billion-dollar adjacent market.
5. Geographic Expansion. Obesity care is overwhelmingly concentrated in the U.S. today. As supply normalizes and international regulatory approvals accumulate, Europe, the Middle East, and parts of Asia represent significant underpenetrated markets. Doustdar's appointment as CEO — with his career-long focus on international operations — signals the company's geographic ambitions.
Key Risks and Debates
Risk 1: Eli Lilly's Competitive Acceleration. Tirzepatide's clinical profile is competitive with semaglutide. Lilly is investing heavily in manufacturing and commercial infrastructure. If tirzepatide achieves superior outcomes in head-to-head trials or reaches market faster in key geographies, Novo's pricing power and market share could erode meaningfully. Novo's stock has already experienced significant drawdowns on competitive clinical trial readouts — a signal that the market views this risk as material.
Risk 2: U.S. Drug Pricing Reform. GLP-1 drugs cost approximately $1,000/month out-of-pocket in the U.S. Political pressure to reduce prices — through Medicare negotiation authority, IRA provisions, or public outrage — is intense and bipartisan. Jørgensen testified before the U.S. Senate on Wegovy pricing. Any meaningful price compression in the U.S. market would disproportionately impact Novo's most profitable franchise.
Risk 3: Supply-Demand Mismatch. Novo has committed billions to manufacturing expansion, but biologics facilities take years to build, validate, and ramp. If demand growth outpaces capacity expansion, the company cedes market share to competitors and compounders. If demand growth slows (due to pricing changes, competitive entry, or safety concerns), the company risks overcapacity.
Risk 4: Compounding Pharmacy Erosion. The $1 billion annual market in compounded semaglutide copies exploits FDA shortage-list provisions that Novo cannot directly control. While these copies are lower-quality and carry safety risks, they serve price-sensitive patients and create a shadow market that undermines brand pricing. The risk persists as long as supply shortages continue.
Risk 5: The Patent Cliff of 2032. Semaglutide's U.S. patent expires in 2032. Unless next-generation molecules (CagriSema, amycretin) achieve clearly superior clinical profiles, the company faces a classic pharma patent cliff — rapid revenue erosion as biosimilar and generic competition enters. The pipeline must deliver within seven years.
Why Novo Nordisk Matters
Novo Nordisk matters to operators and investors not because it invented a blockbuster drug — the pharmaceutical industry produces those regularly — but because it demonstrates what happens when a company compounds domain expertise, patient relationships, and manufacturing capability within a single therapeutic area for a hundred years, and then an inflection point arrives that converts that accumulated depth into explosive growth.
The GLP-1 revolution didn't happen to Novo Nordisk randomly. It happened because every strategic decision the company made for a century — staying narrow, building hospitals, investing in delivery devices, engineering governance for patience, competing with itself, treating manufacturing as a strategic asset — created the preconditions for this particular molecule, at this particular moment, to generate this particular outcome. The playbook principles are not separable from the result. They are the result.
The cautionary dimension is equally important. Novo Nordisk is now a company whose market capitalization reflects expectations of sustained dominance in a market that did not exist five years ago, facing a competitor (Lilly) with comparable resources and arguably superior pipeline optionality, in a political environment that views its pricing as indefensible, with a governance structure that may be too patient for a market moving at venture-backed speed. The same narrowness that generated the opportunity creates the risk. The same patience that enabled the science may not be fast enough for the competition.
For a hundred years, Novo Nordisk bet that depth would beat breadth. For most of that century, the bet looked modest. In the past five years, it has looked visionary. Whether it continues to look visionary depends on whether the company can do the hardest thing in business: change its speed without changing its soul.
